Table 2.

Proportion of patients who deteriorated to peripheral oxygen saturation <90% in room air, required supplemental oxygen therapy above high flow, or experienced mortality due to COVID-19 up to Day 28 (primary efficacy endpoint) and logistic regression model with treatment as a fixed effect and age, body mass index, at least one high-risk factor and at least one COVID-19 vaccine as covariates

			Primary efficacy endpoint	Logistic regression model
	Regdanvimab	SoC	% difference (95% CI) [P-value]a,b	Odds ratio (95% CI) [P-value]c
Overall study cohort	13/418 (3.1)	30/304 (9.9)	-6.8 (-10.9, -2.8) [0.0002]	0.4241 (0.2108, 0.8532) [0.0162]
Delta variant subgroup	8/297 (2.7)	8/115 (7.0)	-4.3 (-10.8, 0.2) [0.0827]	0.3395 (0.1168, 0.9873) [0.0473]

Data are n (%), unless otherwise specified.

^aFarrington and Manning method used to calculate the 95% exact CI for the proportion difference between regdanvimab and SoC cohort in each group

^bP-values were derived from Fisher exact test

^cP-value calculated as a treatment effect from logistic model.

CI, confidence interval; SoC, standard of care.